Nurofen for Children Six Plus Orange 200mg/5ml Oral Suspension
- Name:
Nurofen for Children Six Plus Orange 200mg/5ml Oral Suspension
- Company:
Reckitt Benckiser Ireland Limited
- Active Ingredients:
- Legal Category:
Supply through pharmacy only
Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 28/02/20
(Click to Download)Click on this link to Download PDF directly
Reckitt Benckiser Ireland Limited
Company Products
When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.
Updated on 28 February 2020 PIL
Reasons for updating
- Change to section 4 - possible side effects
Free text change information supplied by the pharmaceutical company
Addition od DRESS text
Updated on 28 February 2020 SmPC
Reasons for updating
- Change to section 4.8 - Undesirable effects
Legal category: Supply through pharmacy only
Free text change information supplied by the pharmaceutical company
Addition of DRESS text
Updated on 28 February 2020 PIL
Reasons for updating
- Change to section 4 - possible side effects
Free text change information supplied by the pharmaceutical company
Addition of DRESS text
Updated on 15 January 2020 PIL
Reasons for updating
- Change to section 6 - manufacturer
Updated on 21 October 2019 SmPC
Reasons for updating
- Improved presentation of SmPC
Legal category: Supply through pharmacy only
Updated on 5 June 2018 SmPC
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 4.3 - Contraindications
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 5.1 - Pharmacodynamic properties
Legal category: Supply through pharmacy only
Free text change information supplied by the pharmaceutical company
Section 4.2: Amendment of text regarding dosing spoon
Section 4.3: Addition of "in patients with severe heart failure (NYHA IV)
Section 4.4: Addition of text in relation to cardiovascular and cerebrovascular effects
Section 4.5: Addition of data in relation to Acetylsalicylic acid
Section 5.1: Addition of text in relation to pharmacodynamic studies
Updated on 7 March 2016 PIL
Reasons for updating
- New PIL for new product
Updated on 7 March 2016 PIL
Reasons for updating
- Change to warnings or special precautions for use
- Change of contraindications
- Change to information about pregnancy or lactation
Updated on 4 March 2016 SmPC
Reasons for updating
- New SmPC for new product
Legal category: Supply through pharmacy only
Updated on 4 March 2016 SmPC
Reasons for updating
- Change to section 2 - Qualitative and quantitative composition
- Change to section 3 - Pharmaceutical form
- Change to section 4.2 - Posology and method of administration
- Change to section 4.3 - Contraindications
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.6 - Pregnancy and lactation
- Change to section 4.8 - Undesirable effects
- Change to section 4.9 - Overdose
- Change to section 5.1 - Pharmacodynamic properties
Legal category: Supply through pharmacy only
Free text change information supplied by the pharmaceutical company
Updated on 21 August 2014 PIL
Reasons for updating
- Addition of information on reporting a side effect.
Updated on 31 July 2014 SmPC
Reasons for updating
- Change to section 4.8 - Undesirable effects
Legal category: Supply through pharmacy only
Free text change information supplied by the pharmaceutical company
Updated on 4 February 2014 SmPC
Reasons for updating
- Change to section 6.5 - Nature and contents of container
Legal category: Supply through pharmacy only
Free text change information supplied by the pharmaceutical company
Updated on 29 January 2014 PIL
Reasons for updating
- Introduction of new pack/pack size
Updated on 12 June 2012 SmPC
Reasons for updating
- Change to section 4.2 - Posology and method of administration
Legal category: Supply through pharmacy only
Free text change information supplied by the pharmaceutical company
Dosage table in Section 4.2 now states the following:
4.2 Posology and method of administration
|
Child’s age (Weight) |
Quantity and method of administration |
Frequency (in a 24 hour period) |
|
6-9 years (20-30kg) |
1 x 200mg/5ml (one 5ml spoonful (large end)) |
3 times |
|
9-12 years (30-40kg) |
1 x 300mg/7.5ml (one 5ml spoonful (large end) and one 2.5ml spoonful (small end)) |
3 times |
Doses should be given approximately every 6 to 8 hours.
For patients with sensitive stomachs it is recommended that Nurofen for Children is taken during a meal
Not intended for children under 6 years of age or under 20kg.
For oral use.
Updated on 10 April 2012 PIL
Reasons for updating
- Change to dosage and administration
Updated on 16 May 2011 PIL
Reasons for updating
- New PIL for new product
Updated on 16 May 2011 SmPC
Reasons for updating
- New SPC for new product
Legal category: Supply through pharmacy only